课题基金 / 基金详情

Mitochondrial Aconitase and Parkinson's Disease

Mitochondrial Aconitase and Parkinson's Disease
线粒体乌头酸酶和帕金森病
批准号:
7152495
负责人:
MANISHA N PATEL
金额:
$31.67万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-12-01 至 2008-11-30

项目摘要

项目成果

MANISHA N PATEL的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):本提案的长期目标是阐明帕金森氏病(PD)患者线粒体氧化应激导致多巴胺能神经元死亡的机制。帕金森病中线粒体氧化应激、生物能量下降和铁超载并共同导致年龄相关神经元死亡的确切机制尚不清楚。据推测,帕金森氏病的神经元损伤部分是由于线粒体乌头酸酶氧化失活引起的直接超氧自由基毒性所致。该假说预测,由于络合物I抑制或多巴胺代谢异常而产生的超氧化物产生,使含有[4Fe-4S]Z+的线粒体乌头酸酶失活,导致乌头酸酶活性丧失,释放Fez+和H202。因此,这种关键的TCA循环酶的翻译后修饰会导致铁负荷增加,氧化剂负荷增加,生物能量下降。线粒体乌头酸酶基因5‘端非翻译区的铁反应元件(IRE)的存在为帕金森病的铁失调提供了另一种机制。该提案将利用人类帕金森病样本、帕金森病动物模型(1-甲基-4-苯基-L、2,3,6-四氢吡啶和6-羟基多巴胺)和多巴胺能细胞培养模型,并结合各种工具和技术,包括生化分析、共聚焦显微镜、分子生物学和转基因/基因敲除/衰老小鼠。具体目标1将确定线粒体乌头酸酶在人类和实验性帕金森病中是否失活。衰老和慢性线粒体氧化应激的影响将通过缺乏线粒体关键抗氧化剂MnSOD的小鼠来确定。具体目标2将确定线粒体乌头酸酶失活是否有助于铁稳态受损。具体目标3将确定使用天然或合成抗氧化剂(例如,MnSOD转基因小鼠或金属卟啉)清除线粒体超氧化物歧化是否能保护线粒体乌头酸酶失活,其方式与减少实验性帕金森病的铁超载和神经元死亡相关。具体目标4将确定实验性帕金森病中线粒体乌头酸酶失活的下游后果。具体地说,5‘IRE对脑线粒体乌头酸酶合成的调节、对TCA循环能力的影响以及乌头酸酶基因沉默的直接神经毒性将被检测。这些研究可以促进我们对帕金森氏病神经元死亡的氧化机制的理解,并为拯救神经元从年龄相关的神经变性中拯救出来提供新的治疗策略。此外,这一系列调查可能解释了帕金森氏症是由年龄和环境因素引起的遗传因素引起的。
英文摘要
DESCRIPTION (provided by applicant): The long-term goal of this proposal is to elucidate the mechanism by which mitochondrial oxidative stress produces dopaminergic neuronal death in Parkinson's Disease (PD). The precise mechanism by which mitochondrial oxidative stress, bioenergetic decline and iron overload arise and collaborate to produce age-related neuronal death in Parkinson's disease remains unclear. It is hypothesized that neuronal damage in Parkinson's disease results, in part from direct superoxide radical toxicity due to oxidative inactivation of mitochondrial aconitase. The hypothesis predicts that superoxide production, arising from Complex I inhibition or abnormal dopamine metabolism, inactivates [4Fe-4S]Z+-containing mitochondrial aconitase, resulting in loss of aconitase activity and release Fe z+ and H202. Posttranslational modification of this key TCA cycle enzyme can therefore result in an increased iron load, oxidant burden and bioenergetic decline. The presence of an iron responsive element (IRE) in the 5' untranslated region of the mitochondrial aconitase Mrna provides an additional mechanism for iron dysregulation in Parkinson's disease. The proposal will utilize human PD samples, animal models of PD (1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine and 6-hydroxydopamine) and dopaminergic cell culture models in conjunction with a diversity of tools and techniques that include biochemical analyses, confocal microscopy, molecular biology and transgenic/knockout/aging mice. Specific Aim 1 will determine whether mitochondrial aconitase is inactivated in human and experimental Parkinson's disease. The influence of aging and chronic mitochondrial oxidative stress will be determined using mice deficient in MnSOD, a critical mitochondrial antioxidant. Specific Aim 2 will determine whether mitochondrial aconitase inactivation contributes to impaired iron homeostasis. Specific Aim 3 will determine whether scavenging mitochondrial superoxide using native or synthetic antioxidants (e.g. MnSOD transgenic mice or metalloporphyrins) protect against mitochondrial aconitase inactivation in a manner that correlates with decreased iron overload and neuronal death in experimental Parkinson's disease. Specific Aim 4 will determine the downstream consequences of mitochondrial aconitase inactivation in experimental Parkinson's disease. Specifically, regulation of brain mitochondrial aconitase synthesis by the 5' IRE in its mRNA, impact on the TCA cycle capacity and direct neurotoxicity of aconitase gene silencing will be examined. These studies can advance our understanding of the oxidative mechanisms of neuronal death in Parkinson's disease and suggest novel therapeutic strategies for rescuing neurons from age-related neurodegeneration. Additionally, this line of investigation may explain Parkinson's disease arising from genetic factors uncovered by aging as well as environmental factors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mitochondrial Sirtuin-3 dysregulation in epileptogenesis
  • 批准号:
    9385643
  • 项目类别:
  • 资助金额:
    $4.82万
  • 财政年份:
    2017
  • 负责人:
    MANISHA N PATEL
  • 依托单位:
Redox Control of Seizure-Induced Neuroinflammation.
  • 批准号:
    10438313
  • 项目类别:
  • 资助金额:
    $5.63万
  • 财政年份:
    2013
  • 负责人:
    MANISHA N PATEL
  • 依托单位:
Gamma-ketoaldehydes in epileptogenesis
  • 批准号:
    9096914
  • 项目类别:
  • 资助金额:
    $34.11万
  • 财政年份:
    2013
  • 负责人:
    MANISHA N PATEL
  • 依托单位:
Redox Control of Seizure-Induced Neuroinflammation.
  • 批准号:
    10439766
  • 项目类别:
  • 资助金额:
    $34.02万
  • 财政年份:
    2013
  • 负责人:
    MANISHA N PATEL
  • 依托单位:
海外基金